Laurus Labs is currently trading at Rs. 335.00, up by 2.85 points or 0.86% from its previous closing of Rs. 332.15 on the BSE.
The scrip opened at Rs. 329.95 and has touched a high and low of Rs. 341.70 and Rs. 328.00 respectively. So far 389 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 418.20 on 01-Nov-2019 and a 52 week low of Rs. 298.00 on 07-Aug-2019.
Last one week high and low of the scrip stood at Rs. 349.05 and Rs. 326.60 respectively. The current market cap of the company is Rs. 3551.17 crore.
The promoters holding in the company stood at 32.73%, while Institutions and Non-Institutions held 44.67% and 22.60% respectively.
US Food and Drug Administration (USFDA) has completed, pre-approval inspection (PAI) at Laurus Labs’ API manufacturing 1&3 Units, located at J N Pharma City, Parawada, Visakhapatnam in the state of Andhra Pradesh.
The inspection ended with three observations, which are procedural in nature and no data integrity issues were observed in the inspection. The inspection was carried out from November 18, 2019 to November 21, 2019.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.